Compare Natera Inc. Common Stock (NTRA) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Synchrony Financial — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Synchrony Financial trades at $71.41 (market cap $23.94B). The key difference: Natera Inc. Common Stock is far larger — about 2.4× Synchrony Financial's market cap, and Synchrony Financial pays a 1.85% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Synchrony Financial for 30 Days on average.
| NTRA | SYF | |
|---|---|---|
Market Cap | $57.03B | $23.94B |
Volume | 1,131,157 | 2,618,932 |
Sector | Health | Financials |
52-Week High | $425.64 | $88.47 |
52-Week Low | $179.42 | $63.78 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $56.18B | $24.18B |
Dividend Yield | — | 1.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Synchrony Financial (SYF) trades at $73.59, down slightly by 0.04% on the day. The stock exhibits a bullish technical signal overall, with support near $73 and resistance at $75. Fundamentally, the company shows strong profitability with a 23.4% net income margin and a compelling valuation at a P/E of 7.55. Recent earnings have consistently beaten expectations, and strategic partnerships, like the one with OpenAI announced on August 17, 2026, highlight growth initiatives.
The outlook for SYF is positive, supported by robust analyst sentiment with a consensus price target of $87.50, implying significant upside. Key opportunities include high ROE and strategic expansions in digital finance. Risks involve potential consumer credit deterioration, as noted in broader market news on August 26, 2026, and increased investing cash outflows in 2026, which could pressure near-term liquidity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
